Solutions for in- and out-licensing
We work closely with phama companies in the process of evaluating new compounds and technologies to be acquired or partnered with.
We help de-risk scientific decisions for in-licensing processes, helping pharma companies to invest in the safest and most effective compounds offered.
Besides, we can also work from the small company perspective, helping them differentiate their compound portfolio by ensuring potential buyers that:
- The MoA is well understood
- The compounds are safe
- All the range of potential indications for the compounds are well understood, thus adding value to the comanies portfolio.
- Our process provides the following advantages:
- Quick delivery of results (3-4 weeks)
- Evaluation of main safety risks of compounds or technologies.
- Prediction of future potential indications related with the mechanism of action.
- Comprehensive future market value evaluation: benchmark against other investigative drugs in class, comparative safety and efficacy, product differentiation, possible combinations and benchmark against standard of care.
For more information visit the sections: